UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549
 
——————
 
FORM 8-K
 
——————
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of
 
the Securities Exchange Act of 1934
 
Date of Report (Date of Earliest Event Reported):
July 2, 2019
 
USANA HEALTH SCIENCES, INC.
(Exact name of registrant as specified in its charter)
 
Utah
(State or other jurisdiction of incorporation)
 
001-35024
87-0500306
(Commission File No.)
(IRS Employer Identification

3838 West Parkway Boulevard
Salt Lake City, Utah 84120
(Address of principal executive offices, Zip Code)
Registrant's telephone number, including area code: (801) 954-7100
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class                                                                                                     Trading
                                                                                                                                  Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value per share                                                                           USNA
 
New York Stock Exchange
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company   ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐
 


Item 2.02                          Results of Operations and Financial Condition.

On July 2, 2019, USANA Health Sciences, Inc. (the “Company” or “USANA”) issued a press release announcing its preliminary financial results for the second quarter ended June 29, 2019 along with updated outlook for the full year 2019.  A copy of the press release is furnished herewith as Exhibit to this Current Report on Form 8-K and is incorporated herein by reference.  This document will be posted on the Company’s corporate website, www.usana.com.

The information in this Current Report is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. The furnishing of the information in this Current Report is not intended to, and does not, constitute a representation that such furnishing is required by Regulation FD or that the information this Current Report contains is material investor information that is not otherwise publicly available.

Item 7.01                          Regulation FD Disclosure

The information disclosed above under Item 2.02, as well as the exhibit attached under Item 9.01 below is incorporated herein by reference.

Item 9.01                          Financial Statements and Exhibits.

(d) Exhibits
  Exhibit No.  
Description
  99.1
 
Press release issued by USANA Health Sciences, Inc. dated July 2, 2019 (furnished herewith).




SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
USANA HEALTH SCIENCES, INC.
 
 
 
 
 
 
 
 
 
By: /s/ G. Douglas Hekking                           
 
G. Douglas Hekking, Chief Financial Officer

Date:  July 2, 2019
 


Exhibit Index

  Exhibit No.  
Description
  99.1